Cpex collaborates with Serenity for intranasal urology drug

Serenity’s drug candidate will be delivered using Cpex’s patented drug delivery technology. Serenity believes the drug targets a potential worldwide market of $2-$3 billion.

The collaboration between Serenity and Cpex began in September 2007 as a feasibility study and advanced to the signing of a development and license agreement in February 2008. Serenity has filed an investigational new drug application with the FDA to initiate Phase I clinical testing.

John Sedor, president and CEO of Cpex, said: “Cpex provided access to its intellectual property, developed the formulations, produced a pilot scale manufacturing process and prepared clinical and stability supplies. Our expertise in product and process development and Serenity’s clinical expertise in specialty areas have quickly proven to be a complementary fit.”